ORFORGLIPRON FOR OBESITY TREATMENT IN OLDER PATIENTS ≥65 YEARS WITH OR WITHOUT TYPE 2 DIABETES: A POST HOC SUBGROUP ANALYSIS OF THE ATTAIN-1 AND ATTAIN-2 TRIALS

Descargar Publicación
Consenso multidisciplinario chileno sobre el uso de agonistas de GLP-1: Recomendaciones basadas en metodología GRADE Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial